Novartis.com | Contact Us | Help | Site Map | Stay Connected | Large Text VersionRegular Text Version

Welcome to Novartis Oncology - The Global Site

 

 

 

Novartis Oncology Media

Media

This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room

ZOMETA® (zoledronic acid)

ZOMETA® (Zoledronic Acid)

ZOMETA CONTACT

Megan Humphrey
Novartis Oncology Global Public Relations
office +1-862-778-6724

ZOMETA® is indicated for the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone or tumour-induced hypercalcameia) in patients with advanced malignancies involving bone.

  • Treatment of tumor-induced hypercalcemia
 

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

ZOMETA Images

 
 

ABOUT NOVARTIS ONCOLOGY

Learn More About Novartis Oncology

We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.

 
 

Novartis Oncology

Oncology News is a current news service provided by Doctor's Guide®. Novartis accepts no responsibility for and makes no representations or warranties regarding the content of the information presented.

Ok